Xanthine Oxidase Inhibitor Drug Class List

Drugs in Drug Class: Xanthine Oxidase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009	AB	RX	Yes	No
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009	AB	RX	Yes	No
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009	AB	RX	Yes	Yes
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009	AB	RX	Yes	Yes

Last updated: July 19, 2026

Xanthine Oxidase Inhibitor Market Dynamics and Patent Landscape (Allopurinol, Febuxostat, Topiroxostat)

Executive summary: The xanthine oxidase inhibitor (XOI) market is dominated by generic allopurinol and branded febuxostat, with patent and exclusivity-driven dynamics concentrated in the febuxostat value chain and in niche agents (notably topiroxostat) depending on geography. Patent estates for core XOIs are largely matured, shifting competition to (1) new salt/polymorph/formulation variants, (2) pediatric or dosing-regimen IP, (3) combination products, and (4) follow-on indications. Near-term market changes are driven less by primary compound patents and more by Orange Book listings, exclusivity expirations, and residual formulation or method-of-use protection. Key licensing and litigation activity is concentrated where brands still have enforceable Orange Book barriers to generic entry, especially for febuxostat in jurisdictions where follow-on patents remain active.

Key XOI takeaways for business planning

Theme	Practical implication for R&D, licensing, and litigation
Most primary XOI small-molecule patents are older	Watch follow-on patents: polymorphs, salts, granulations, tablet/coating systems, and manufacturing methods.
Market share is already generic-heavy for urate lowering	Commercial leverage sits in supply chain reliability, payer contracting, and differentiated safety/dosing evidence rather than compound novelty.
Febuxostat is the patent and brand focal point	Competitive entry timing depends on Orange Book listings and any unexpired method-of-use or formulation patents tied to approved dosing.
Litigation risk is episodic	Paragraph IV and settlement patterns matter where there is still enforceable Orange Book coverage.
Claims are often claim-narrow and form/step specific	Patent landscapes must map claim scope to the exact marketed dosage form and manufacturing process.

---

What patents protect xanthine oxidase inhibitors (allopurinol vs febuxostat vs topiroxostat)?

Answer: XOI patent coverage, where enforceable today, is concentrated in follow-on IP rather than foundational xanthine oxidase inhibition compositions. Protection typically falls into four buckets: (1) formulations (salt/polymorph, excipients, coatings), (2) manufacturing methods (granulation, drying, compression parameters), (3) dosing regimens and method of treatment (including patient subgroups), and (4) combination products and distinct controlled-release or bioavailability improvements.

Allopurinol: what the patent estate usually looks like

• Core allopurinol composition protections are long expired in most major markets; market competition relies on generic manufacturing quality and regulatory equivalence rather than enforceable brand IP.
• Remaining IP (where present) tends to be narrow and product-specific: specific excipient blends, tablet manufacturing steps, and possibly pediatric formulations tied to a particular sponsor’s dossier.

Febuxostat: where enforceable IP tends to cluster

• Febuxostat retains branded commercial positioning in multiple regions, and the remaining enforceable estate is typically in:
  • Specific crystalline forms or solid-state states (including polymorph and hydrate forms)
  • Controlled-release or bioequivalence-improvement formulations
  • Method-of-use claims aligned with approved indications or dosing regimens
  • Patents directed to manufacturing and impurity profiles for low-bioavailability variability

Topiroxostat: niche brand dynamics by geography

• Topiroxostat follows a similar follow-on pattern: formulations and solid-state IP can remain relevant depending on jurisdiction and local approvals.
• Competitive entry risk correlates with the presence of local Orange Book-like patent listings and regulatory data exclusivity status.

---

When does febuxostat lose exclusivity and patent protection for generic entry?

Answer: For XOI class members, the gating factor is usually the last-to-expire among (a) formulation and method-of-use patents in the local patent register (Orange Book in the US or equivalent in other territories) and (b) any data exclusivity periods tied to the specific approved formulation/indication.

What to model for launch timing

Timing driver	What to check in Orange Book (US) or local registers
Last active patent expiration	Earliest generic “carve-out” depends on the last-to-expire listing tied to the marketed dosage form
Exclusivity code(s)	3-year new clinical investigation, 5-year new chemical entity, 7-year pediatric exclusivity only if triggered, and other regional exclusivity constructs
Method-of-use coverage	Whether patents cover use that maps to the labeling wording on the approved comparator reference product
Formulation coverage	Whether marketed tablet strengths match the claim scope on the listed formulation patents

Business impact: Generic entry windows often compress into a “single barrier period” rather than multiple staggered dates. That makes it critical to map each listed patent to the strength and dosage form being targeted.

---

What Paragraph IV challenges exist for xanthine oxidase inhibitors, and which companies are likely to file?

Answer: In mature drug classes like XOIs, Paragraph IV challenges are less frequent at the class level and more frequent where a brand still has enforceable Orange Book patents or where a specific follow-on formulation remains protected. Generic challengers target the weak link: a method-of-use claim that can be designed around, a formulation patent with narrow claim scope, or a manufacturing method patent that can be avoided by process changes.

How generic applicants typically design around XOI barriers

• Target a different salt/solid state, if allowed by the regulator’s bioequivalence pathway
• Use a different manufacturing route that avoids claimed process steps
• Pursue a different excipient system or tablet architecture not captured by claim limitations
• File strength-selective ANDAs to test whether certain strengths have less restrictive coverage

What litigation patterns to expect

• Settlement tends to follow a “design-around confirmation” model where the generic agrees to a delayed launch date while preserving its process flexibility.
• Injunction outcomes usually hinge on claim construction and infringement fit to the exact dosage form in the FDA labeling.

---

What is the Orange Book status of febuxostat and other xanthine oxidase inhibitors?

Answer: Orange Book status is where actionable launch timing is determined in the US. For the XOI class, most older compounds will have limited or no active listed patents. Market-relevant entries typically center on febuxostat (and any specific follow-on formulations) for which listed patents can still block or narrow FDA approval routes.

Orange Book mapping framework (use for each marketed XOI strength)

Orange Book item	Action for competitive strategy
Listed patents by drug product/strength	Build an “AND A risk matrix” by strength
Expiration dates	Identify the first day the last blocking patent expires and compute practical generic launch readiness
Exclusivity periods	Check whether exclusivity blocks the ANDA even when patents expire
Labeling tie	Assess whether the generic must include carve-outs tied to the patented indication

---

How strong is the patent estate for xanthine oxidase inhibitors?

Answer: Patent strength in XOIs is typically “high for follow-on” and “low for the base compound.” The stronger estates are the ones that are (1) still active, (2) tightly claim manufacturing and formulation specifics, and (3) map directly to the labeled dosage forms and approved indications.

Patent strength scoring model for XOI follow-on estates

Factor	Stronger profile	Weaker profile
Claim scope	Claims cover a narrow but unavoidable design feature of the marketed tablet/capsule	Claims are broad but easy to design around without clinical performance loss
Enablement and written description	Strong disclosure matching commercial process	Disclosure mismatch that weakens validity/infringement
Prosecution history	Narrowing amendments create predictable vulnerability	No clear prosecution estoppel but strong enforceability
Litigation posture	Active suits against multiple generics	No enforcement track record, suggesting low expected injunction odds
Regulatory tie	Patents explicitly link to the exact FDA-approved formulation	Patents cover theoretical compositions not used in the marketed product

---

What formulations are protected by xanthine oxidase inhibitor patents (salts, polymorphs, tablets)?

Answer: The protected formulation layer typically covers:

• Crystalline forms and solid-state properties (polymorph/hydrate)
• Tablet core composition (active loading window, excipient ratios)
• Coatings and film systems affecting dissolution and bioavailability
• Granulation and compression processes that control impurity and hardness

Formulation claim targets relevant to generic design

Claim target	Why it blocks entry	Typical generic workaround
Polymorph/hydrate	Requires matching solid-state state to infringe	Use alternate solid state with equivalent bioavailability
Dissolution profile	Method-of-use or formulation claims may imply dissolution targets	Tune dissolution via formulation adjustments not captured by claims
Impurity control	Manufacturing method patents tie to impurity specs	Use different purification/processing route
Tablet architecture	Coating thickness, binder type, and process steps	Adopt a different tablet design not matching claim limits

---

What method-of-use patents affect urate lowering and gout management for xanthine oxidase inhibitors?

Answer: Where method-of-use patents remain, they commonly relate to:

• Dosing regimen (titration schedule or fixed dosing strategy)
• Patient subpopulations (renal impairment thresholds, refractory gout categories, hyperuricemia subtypes)
• Treatment endpoints tied to specific clinical outcomes (urate targets and time-to-target concepts)

Infringement risk test

• Method-of-use patents hinge on whether a generic’s labeling induces or directs the practicing steps.
• If patents are written to the exact labeled dosing, entry risk rises and settlements more often lock launch dates.

---

How does febuxostat compare with allopurinol in market dynamics, safety positioning, and IP barriers?

Answer:

• Allopurinol’s market behavior is driven by generic abundance and limited brand-level IP barriers.
• Febuxostat’s market behavior remains more sensitive to patent and exclusivity residuals, with a stronger link between regulatory labeling, payer access, and the enforceability of follow-on patents.

Commercial and competitive contrast

Dimension	Allopurinol	Febuxostat
Patent barrier	Low in most markets	Higher where follow-on formulation/method-of-use patents persist
Competitive structure	Many interchangeable generics	Mix of generics and branded share; entry timing can be barrier-driven
Differentiation	Price and supply	Evidence base, labeling positioning, and dosing convenience
Launch risk for generics	More predictable	Depends on last Orange Book listing and exclusivity blocks

---

What manufacturing/IP barriers block generic xanthine oxidase inhibitors?

Answer: The dominant barriers are not end-user physician behavior; they are process- and solid-state-linked constraints that claim infringement depends on. For tablet small molecules, manufacturing design-around can be effective, but it must preserve dissolution, impurity control, and equivalence metrics.

Process-linked barriers to model

• Drying/solvent removal steps tied to specific impurity profiles
• Granulation end-point parameters (e.g., moisture content, particle size distribution)
• Compression and tablet hardness targets affecting dissolution curves
• Coating formulation and coating thickness ranges

---

What regulatory status and exclusivity periods govern xanthine oxidase inhibitors in the US FDA pathway?

Answer: XOI small molecules generally reach patients via ANDA pathways for generics and 505(b)(2) pathways for reformulations. The critical gating items are:

• Whether the reference product has unexpired listed patents
• Whether exclusivity applies to the specific NDA/BLA supplement tied to the marketed dosage form

Pathway risk mapping

Scenario	Regulatory behavior	IP interaction
ANDA to generic a tablet strength	FDA acceptance depends on patent certifications	“Paragraph IV + settlement” can delay launch
505(b)(2) for reformulation	Requires bridging to the reference	Follow-on formulation patents can block approval if listed
Pediatric supplement	Pediatric exclusivity can extend	Launch timing changes even if base patent ends

---

Key licensing and settlement dynamics in xanthine oxidase inhibitor disputes

Answer: Where patents remain, deals commonly follow a settlement structure that fixes a launch date in exchange for dismissal or non-enforcement for a defined claim set. Licensing strategies typically focus on:

• Obtaining freedom-to-operate for specific strengths
• Securing rights to use a specific solid state or manufacturing know-how
• Narrowly licensing formulation improvements with clear non-overlap

Deal terms typically relevant to XOI assets

Term	Why it matters
Launch-date commitment	Determines ROI for generic manufacturing scale-up
Claim release scope	Defines which patents are still enforceable post-settlement
Strength coverage	Settlements often cover some strengths but leave others
Territory allocation	Deals can be US-only with separate foreign arrangements

---

Regional dynamics: where competition changes fastest for xanthine oxidase inhibitors?

Answer: Competition accelerates fastest where (1) primary compound IP is fully expired and (2) local regulators support rapid generic approval. The remaining sensitivity zones are markets with active follow-on formulation/method-of-use IP and where local patent registers provide enforcement leverage.

Geographic pattern

Region	Typical competitive state	What to watch
US	Orange Book enforcement determines timing	Active listed patents and exclusivity tied to marketed strengths
EU	National patent enforcement matters	SPCs and national court rulings for follow-on IP
Japan/Korea	Brand residue can persist	Local filings and data exclusivity nuances for specific formulations
LatAm/MENA	Faster generic penetration common	Local litigation and product dossier exclusivity

---

Key Takeaways

• Xanthine oxidase inhibitor competition is increasingly governed by follow-on IP, not base compound patents.
• Febuxostat is the most operationally sensitive area where Orange Book-listed formulation and method-of-use patents can still move generic entry dates.
• Generic risk is strongest when patents tie to the marketed strength and labeling language through method-of-use or unavoidable solid-state features.
• The most actionable diligence target is the last-to-expire patent and exclusivity item for each marketed strength, then mapping claim scope to the generic’s design-around plan.

---

FAQs

1. Which xanthine oxidase inhibitor patents most commonly block 505(b)(2) reformulations?
2. How do polymorph and hydrate patents affect generic equivalence for febuxostat tablets?
3. What labeling language drives method-of-use infringement risk for urate-lowering regimens?
4. Do manufacturing method claims for tablet XOIs survive better than compound claims in litigation?
5. What settlement structures most often appear in XOI Paragraph IV disputes, and how do they split by strength?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
2. FDA. Drug Development and Approval Process (ANDAs, 505(b)(2), exclusivity and patent certification framework). US Food and Drug Administration.